Pharmacological Activation of Estrogen Receptor Beta Overcomes Tumor Resistance to Immune Checkpoint Blockade Therapy

Shuang Huang, Nianxin Zhou, Linjie Zhao, Ryan C. Gimple, Young Ha Ahn, Peidong Zhang, Wei Wang, Bin Shao, Jingyun Yang, Qian Zhang, Sai Zhao, Xuehan Jiang, Zhiwei Chen, Yangfan Zeng, Hongbo Hu, Jan Åke Gustafsson, Shengtao Zhou

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

The emerging immune checkpoint blockade (ICB) therapy has ushered the cancer therapeutics field into an era of immunotherapy. Although ICB treatment provides remarkable clinical responses in a subset of patients with cancer, this regimen fails to extend survival in a large proportion of patients. Here, we found that a combined treatment of estrogen receptor beta (ERβ) agonist and PD-1 antibody treatment improved therapeutic efficacy in mouse tumor models, compared with monotherapies, by reducing infiltration of myeloid-derived suppressor cells (MDSCs) and increasing CD8+ T cells in tumors. Mechanistically, LY500307 treatment reduced tumor-derived CSF1 and decreased infiltration of CSF1R+ MDSCs in the tumor bed. CSF1 released by tumor cells induced CSF1R+ MDSC chemotaxis in vitro and blockade of CSF1R demonstrated similar therapeutic effects as ERβ activation in vivo. Collectively, our study proved combined treatment of ERβ agonist and PD-1 antibody reduced MDSC infiltration in the tumor and enhanced tumor response to ICB therapy.

Original languageEnglish (US)
Article number101458
JournaliScience
Volume23
Issue number9
DOIs
StatePublished - Sep 25 2020

Keywords

  • Cancer
  • Endocrine Treatment
  • Immunology

ASJC Scopus subject areas

  • General

Fingerprint Dive into the research topics of 'Pharmacological Activation of Estrogen Receptor Beta Overcomes Tumor Resistance to Immune Checkpoint Blockade Therapy'. Together they form a unique fingerprint.

Cite this